Melinta Therapeutics Inc - Strategic SWOT Analysis Review
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy summarization of the companys business strategy.
- SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
Highlights
Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of the various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin and minocycline. Melintas products and pipeline candidates are built on ribosome platform licensed from Yale University. Melinta is headquartered at New Haven, Connecticut, the US.
Melinta Therapeutics Inc Key Recent Developments
Nov 16,2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer
Aug 03,2020: Melinta Therapeutics announces appointment of Christine Ann Miller as President and Chief Executive Officer
Apr 20,2020: Melinta Therapeutics successfully completes financial restructuring
Feb 13,2020: Melinta Therapeutics announces court approval of chapter 11 bidding procedures
Dec 27,2019: Melinta Therapeutics announces restructuring support agreement with its secured lenders under its senior credit facility
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors business structure and strategies with detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Section 1 - About the Company
Melinta Therapeutics Inc - Key Facts
Melinta Therapeutics Inc - Key Employees
Melinta Therapeutics Inc - Key Employee Biographies
Melinta Therapeutics Inc - Major Products and Services
Melinta Therapeutics Inc - History
Melinta Therapeutics Inc - Company Statement
Melinta Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Melinta Therapeutics Inc - Business Description
Melinta Therapeutics Inc - Corporate Strategy
Melinta Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Melinta Therapeutics Inc - Strengths
Melinta Therapeutics Inc - Weaknesses
Melinta Therapeutics Inc - Opportunities
Melinta Therapeutics Inc - Threats
Melinta Therapeutics Inc - Key Competitors
Section 3 Companys Lifesciences Financial Deals and Alliances
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Melinta Therapeutics Inc, Recent Deals Summary
Section 4 Companys Recent Developments
Nov 16, 2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer
Aug 03, 2020: Melinta Therapeutics announces appointment of Christine Ann Miller as President and Chief Executive Officer
Apr 20, 2020: Melinta Therapeutics successfully completes financial restructuring
Feb 13, 2020: Melinta Therapeutics announces court approval of chapter 11 bidding procedures
Dec 27, 2019: Melinta Therapeutics announces restructuring support agreement with its secured lenders under its senior credit facility
Sep 03, 2019: Melinta Therapeutics announces appointment of Jennifer Sanfilippo to interim Chief Executive Officer and Director
Aug 09, 2019: Melinta Therapeutics reports second quarter 2019 financial results and provides business update
Aug 09, 2019: Melinta Therapeutics Names David Gill as chairman and announces CEO succession plan
Jul 16, 2019: Melinta Therapeutics announces preliminary second quarter 2019 financial results and provides corporate update
May 09, 2019: Melinta Therapeutics reports first quarter 2019 financial results and provides corporate update
Section 5 Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List Of Tables
Melinta Therapeutics Inc, Key Facts
Melinta Therapeutics Inc, Key Employees
Melinta Therapeutics Inc, Key Employee Biographies
Melinta Therapeutics Inc, Major Products and Services
Melinta Therapeutics Inc, History
Melinta Therapeutics Inc, Subsidiaries
Melinta Therapeutics Inc, Key Competitors
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Melinta Therapeutics Inc, Recent Deals Summary
List Of Figures
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Melinta Therapeutics Inc (MLNT) - Financial and Strategic SWOT Analysis Review
Melinta Therapeutics Inc (MLNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to
USD 125 View ReportAnika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2021 Update
Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical and veterinary applications. Its major
USD 750 View ReportChinook Therapeutics Inc (KDNY) - Financial and Strategic SWOT Analysis Review
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using
USD 300 View ReportFill The Form For Sample Request